177 results about "Proliferation activity" patented technology

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The present application relates to a kind of purine derivatives as the use of NSD2 and NSD3 inhibitor, the structural formula of the derivative is as shown in formula (I) or formula (II).The compound shows good NSD2, NSD3 inhibitory activity, can effectively reduce the methylation level of H3K36 in cell, and cause the reduction of cell proliferation activity of NSD2, NSD3 high expression tumor cell strain.

The invention discloses a corrosion-resistant and collagen-functionalized magnesium-based metal coating and a preparation method of the corrosion-resistant and collagen-functionalized magnesium-based metal coating. Belongs to the technical field of biomedical material preparation. The preparation method comprises the following steps: firstly introducing hydroxyl into the surface of the magnesium alloy through alkali treatment, then sequentially dipping the magnesium alloy into a solution A and a solution B containing specific copolymers, drying to obtain an anti-corrosion coating, and finally coating with a recombinant humanized collagen solution. The copolymer A in the solution A and a magnesium substrate form a firm Si-O-Mg covalent bond through a silane coupling agent, and the fluorine-containing copolymer B in the solution B is tightly combined with a bottom layer through self-assembly, so that a super-hydrophobic anti-corrosion barrier with a stable structure and strong adhesion is constructed. The outermost collagen layer endows the magnesium alloy material with excellent endothelial cell adhesion and proliferation promoting activity. The multi-layer composite coating structure effectively solves the problems that magnesium alloy degradation is too fast, and an existing coating is weak in binding force and lacks biological functions, and has wide application prospects in implantable medical devices such as intravascular stents.

The invention relates to the technical field of biological medicines, and provides application of ADRM1 gene / protein in preparation of a medicine for treating osteosarcoma. When the ADRM1 gene / protein is applied to the preparation of the medicine for treating osteosarcoma, the proliferation, migration and invasion capabilities of tumor cells can be remarkably inhibited, so that the occurrence and development of osteosarcoma are delayed. The expression of the ADRM1 is knocked down through an shRNA intervention technology, the mRNA and protein level of the ADRM1 in 143b and U2OS osteosarcoma cell lines can be remarkably reduced, the short-term proliferative activity and the long-term clone forming ability of the ADRM1 are further inhibited, and the migration and invasion characteristics of cells are effectively weakened. The growth of a tumor body formed after a nude mouse is inoculated with 143b osteosarcoma cells knocking down ADRM1 is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor body is reduced, which indicates that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of osteosarcoma.

An N-heterocycle-containing boric acid compound and a preparation method and application thereof are provided. The preparation method adopts 3-bromo-1-p-tosyl-1H-pyrrolo[2, 3-b]pyrimidine as a raw material to generate (3-((5-chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)boric acid by three steps of reaction. The (3-((5-chloro-4 (1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)boric acid has good inhibition effect on the proliferation activity of brain glioma, which is proven by cell experiments.

The application discloses a pyrrolobenzodiazepine-anthracene imide hybrid molecule and a preparation method and application thereof, and belongs to the technical field of chemical medicines. In order to solve the problems of few kinds of warheads of an existing antibody drug conjugate, single action mechanism and drug resistance easily generated in long-term use, a pyrrolobenzodiazepine-anthracene imide hybrid molecule shown in formula I and a preparation method and application thereof are provided. Experimental results show that the compound has strong anti-proliferation activity in various tumor cells such as ovarian cancer cells, gastric cancer cells and breast cancer cells, and an antibody drug conjugate thereof has good in-vivo and in-vitro anti-tumor activity and good safety.

The invention discloses application of phloretin in preparation of a medicine for promoting liver cell proliferation, and belongs to the technical field of medicine. A specific cell proliferation tracing system of the hepatocytes is utilized, the proliferation activity of the hepatocytes in an animal body can be continuously recorded, animal experiments find that in the physiological homeostasis maintaining process of a mouse, phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of liver tissue, and it is found through hepatic lobule zoning analysis that phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of the liver tissue. The phloretin can effectively promote proliferation of hepatic cells in the first, second and third regions of the hepatic lobule. Therefore, phloretin is a potential medicine for liver regeneration.

The application discloses a dihydroquinazolinone-containing N-hydroxy amide compound and a preparation method and application thereof, relates to the technical field of medicinal chemistry, and utilizes the splicing principle to design and synthesize dihydroquinazolinone-containing N-hydroxy amide compounds with novel structures, and the compounds are tested in terms of HDAC6 protein affinity and anti-proliferation activity of cervical cancer cell Siha, and the results show that the compounds E1-E5 have better affinity to the HDAC6 protein, the IC 50 values are 4.1-85.4 nM, wherein the affinity of the compound E4 to the HDAC6 protein is higher than that of a positive control SAHA; and the compounds E1-E5 can better inhibit the proliferation of the cervical cancer cell Siha, the IC 50 values are 2.4-9.3 muM, wherein the activity of the compound E4 is the strongest.

The invention discloses an organoid culture medium, a kit and a method for culturing an organoid, and relates to the technical field of organoid culture. The organoid culture medium provided by the invention can improve the proliferation activity of the organoid, a relatively complete organoid form can be obtained through culture, and the cost of the culture medium is reduced. The tumor cell organoid obtained by adopting the organoid culture medium provided by the invention has a more complete tumor cell surface marker, and the cell damage is smaller.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The invention relates to an HDAC1 inhibitor and a preparation method and application thereof. The HDAC1 inhibitor has a structure as shown in a formula (1). The compound shown in the formula (1) shows strong inhibitory activity on HDAC1 protease, and the IC50 value of the compound is basically smaller than 100 nM. Meanwhile, the compound disclosed by the invention also shows strong anti-proliferative activity for MC-38 tumor cells, and the IC50 value of the compound is basically less than 1 mu M, so that the compound disclosed by the invention is expected to be prepared into medicines for treating various HDAC1-mediated related diseases.

The present application belongs to the field of medicinal chemistry and pharmacotherapy, and particularly relates to a chalcone mannich base compound, a pharmaceutical composition and a preparation method and application thereof. The present application takes paeonol as a raw material, and obtains corresponding 3-substituted and 5-amino-methyl-substituted paeonol mannich base through mannich reaction of paeonol, polyoxymethylene and different organic amines. After the 3-substituted and 5-substituted paeonol mannich base is separated through column chromatography, the chalcone mannich base compound is obtained through Claisen-Schmidt reaction of the 3-substituted and 5-substituted paeonol mannich base and benzaldehyde containing different substituents. Experiments prove that the chalcone mannich base compound improves the physical and chemical properties of the chalcone mannich base and improves the drug efficacy, can solve the problem of poor water solubility, and has good anti-tumor cell proliferation activity.

The invention belongs to the technical field of medicines, and relates to an amide compound based on a hydrophobic labeling technology and preparation and application thereof. The structural general formula H of the target product is shown in the specification, or pharmaceutically acceptable salts, solvent compounds or hydrates of the target product. The compound provided by the invention has dual mechanisms of inhibiting polymerization and degradation of tubulin, has an effect of inhibiting tumor proliferation, and has a good prospect in the aspect of development of antitumor drugs.

The application relates to the field of biological medicine, and provides application of ADRM1 gene / protein in preparation of a drug for treating osteosarcoma. The ADRM1 gene / protein is applied to preparation of the drug for treating osteosarcoma, can significantly inhibit proliferation, migration and invasion ability of tumor cells, and thus delays occurrence and development of the osteosarcoma. By shRNA intervention technology, the expression of ADRM1 is knocked down, the mRNA and protein levels of ADRM1 in 143b and U2OS osteosarcoma cell lines are significantly reduced, short-term proliferation activity and long-term clone formation ability are inhibited, and migration and invasion characteristics of the cells are effectively weakened. After 143b osteosarcoma cells with the knocked-down ADRM1 are inoculated into nude mice, the growth of the tumor formed by the cells is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor is down-regulated, indicating that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of the osteosarcoma.

The invention discloses a polypeptide, a recombinant XI type humanized collagen formed by the polypeptide and application of the recombinant XI type humanized collagen. Through a large number of screening studies, it is found that a natural human XI type collagen core functional region of recombinant XI type humanized collagen with a triple helix structure can be formed in the in-vitro biosynthesis process. On the basis, the recombinant humanized polypeptide is designed and prepared on the basis of a natural XI type collagen core functional area, and the polypeptide can form a stable triple-helix structure. The recombinant XI type humanized collagen provided by the invention has good biological activities, including promotion of cell proliferation activity, promotion of cell adhesion activity and promotion of extracellular matrix generation or reconstruction, and is suitable for various medical or non-medical applications.

The invention relates to a lung fibroblast culture method, and belongs to the technical field of cell culture. Comprising the following steps: S1, organization preparation; s2, tissue treatment; s3, primary culture: the treated tissue blocks are attached to a culture dish, a culture solution is added, the culture solution is a primary culture system, and culture is performed in an incubator for several days until the culture dish is full of fibroblasts; s4, subculture: digesting the cells subjected to primary culture by adopting conventional 0.25% trypsin, then adding a culture solution which is a subculture system for subculture, and carrying out subculture to a fourth generation; and S5, cell identification. According to the invention, primary and subculture are respectively purified and amplified by virtue of a double culture system of fibroblasts, so that the purification of target cells is facilitated, the cell quality is good, a low-serum growth additive is used as a nutrient substance, the low-serum growth additive is more easily utilized by the cells, the proliferation of the cells is facilitated, and good proliferation activity and phenotypic stability are still kept when the cells are subcultured to the fourth generation; no obvious differentiation phenomenon occurs.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

This invention relates to the fields of stem cell culture and serum-free culture media, specifically to a serum-free culture medium for the proliferation of bovine muscle stem cells and its applications. The serum-free culture medium is based on a serum-free basal culture medium, to which food-derived small molecule compounds are added. Through further combination optimization, four food-derived small molecule compounds with synergistic effects have been obtained. This serum-free culture medium can significantly promote the proliferation of bovine muscle stem cells, effectively maintain cell proliferation activity, and cells passaged using this serum-free culture medium can still maintain good differentiation potential. This provides a stable, sufficient, and safe cell source for the industrial production of cultured meat, which is beneficial for the large-scale production of bovine muscle stem cells.

The invention discloses a method for purifying a recombinant human basic fibroblast growth factor (bFGF). Relates to the technical field of biology. Comprising the following steps: inducing expression of bFGF; soluble protein extraction and primary purification; carrying out primary heparin affinity chromatography purification; the enterokinase of the bFGF trx tag is cut off; and carrying out secondary heparin affinity chromatography purification. The purification process is optimized, so that the product recovery rate is remarkably improved, and the method has the advantage of high large-scale production. The purified bFGF shows remarkable biological activity in a cell proliferation activity experiment; a dose-dependent proliferation promoting effect is shown in a concentration range of 1-10ng / mL; when the concentration is 10ng / mL, the cell proliferation reaches 3.2 + / -0.4 times. Besides, through systematic expression optimization and an innovative purification process, efficient preparation of the high-activity bFGF protein is realized, and a high-quality raw material is provided for the fields of tissue repair and regenerative medicine.

The application discloses the application of Huaxingdan in the preparation of a glioma drug in the technical field of biology and medicine, detects the influence of Huaxingdan on the proliferation activity of glioma cells U251, U87 and A172 by using an MTT method in vitro, finds that Huaxingdan has a significant inhibitory effect on the proliferation of glioma cells, and is time and concentration dependent. The influence of Huaxingdan on the apoptosis of glioma cells U87 is detected by using a flow cytometry, and it is found that Huaxingdan can induce the apoptosis of U87 cells, and is concentration dependent. The animal experiment shows that Huaxingdan can effectively inhibit the growth of glioma cells in vivo, and the HE staining shows that Huaxingdan has no toxicity in vivo, and can be used as a drug for preventing and treating glioma.

The invention relates to the field of medicinal chemistry, and particularly discloses an mTOR / GLS1 double-target inhibitor as well as a preparation method and medical application thereof. The compound is based on a rapamycin structure, an amide side chain containing pyridopyrimidine-thiadiazole substitution is introduced to a 42-O site, and through reasonable Linker connection, double-target synergistic inhibition on mammal rapamycin target protein (mTOR) and glutaminase 1 (GLS1) is realized. The compound can block glycometabolism and glutamine metabolism reprogramming of tumor cells at the same time, so that proliferation and metastasis of the tumor cells are remarkably inhibited, and drug resistance is reduced. In-vivo and in-vitro experiment results show that the compounds show excellent anti-proliferative activity in various breast cancer cell lines, and the representative compound I-4 has a relatively strong inhibition effect on mTOR and GLS1, can significantly inhibit tumor metastasis in an animal model, and has no obvious toxic or side effect. The mTOR / GLS1 double-target inhibitor provided by the invention can be used as an important candidate for developing novel efficient and low-toxicity antitumor drugs.

The present invention relates to an edible medium composition having excellent cell proliferation activity. The edible medium composition according to the present invention has the effect of improving cell proliferation activity and inhibiting cellular senescence. In addition, the edible medium of the present invention is literally composed of raw materials that are edible for humans, and thus can be advantageously used as a culture medium for cell-cultured foods. Cells cultured in the edible medium composition of the present invention exhibit higher food safety while also offering cost advantages, compared to cells cultured in conventional media.

The invention belongs to the technical field of synthetic biology, and particularly relates to a polypeptide, a recombinant XI-type humanized collagen composed of the polypeptide and application of the recombinant XI-type humanized collagen. According to the invention, through a large number of screening researches, a core functional region of a natural human XI type collagen alpha1 (XI) chain and a natural human XI type collagen alpha2 (XI) chain of a recombinant XI type humanized collagen with a triple helix structure can be formed in an in-vitro biosynthesis process. Furthermore, the polypeptide capable of forming the recombinant XI type humanized collagen with the triple-helix structure and the recombinant XI type humanized collagen with the triple-helix structure based on the polypeptide are successfully expressed and prepared for the first time. The recombinant XI type humanized collagen provided by the invention has good biological activity, including promotion of cell proliferation activity and promotion of cell adhesion activity, and is suitable for various medical or non-medical applications.

The invention discloses a targeted protein degradation agent utilizing a ubiquitin-proteasome pathway as well as a preparation method and application of the targeted protein degradation agent, and belongs to the technical field of biological medicines. On the basis of a PROTAC (protein targeted degradation chimera) strategy and on the basis of imatinib, different Linkers are introduced to be connected with an E3 ubiquitin enzyme ligand Nutlin-3 derivative, a degradation tag is labeled on BCR-ABL cancer protein, and the degradation agent with the Bcr-Abl protein targeting capacity is constructed. A Western blot experiment shows that the targeted protein degradation agent shows a good degradation effect on the Bcr-Abl protein in K562 cells, and the compound WP shows a degradation effect on concentration dependence and time dependence of the Bcr-Abl protein. Tumor cell proliferation experiments show that the compound has certain inhibitory activity on K562 cells. Wherein when the Linker is dodecane-1, 12-diketone, the anti-proliferative activity is the best. An apoptosis experiment and a period experiment show that the targeted protein degradation agent can realize concentration-dependent promotion of cell apoptosis and retard cells in S and G1 / G0 periods.

The invention relates to the technical field of livestock breeding biology, and discloses a method for promoting porcine ovary granular cell proliferation, which comprises the following steps: adding a porcine follicular fluid exosome into a porcine ovary granular cell culture system, and acting for a certain time at an effective concentration, so as to improve the proliferation activity of granular cells. After the exosome treatment, the apoptosis rate of granular cells can be reduced, the cell survival rate can be improved, and the granular cells can be promoted to secrete steroid hormones, including the estradiol level and the expression of progesterone synthetase. Cell experiments prove that the follicular fluid exosome can effectively improve the activity of granular cells, promote the process of a cell cycle, inhibit cell apoptosis and remarkably enhance the synthesis capacity of steroid hormones such as estradiol and progesterone, and a new intervention strategy is provided for improving follicular development and reproductive performance of sows.

The invention provides a polypeptide PN-VW22 and application thereof, and belongs to the technical field of polypeptide drugs. The polypeptide PN-VW22 provided by the invention is specifically as follows A1) or A2): A1) an amino acid sequence as shown in SEQ ID NO.1; a2) a fusion protein obtained by connecting a label to the N end or / and C end of A1). The polypeptide has obvious cell proliferation activity and anti-staphylococcus aureus bifunctional activity, and also has a wound repairing effect. The polypeptide is small in molecular weight and stable in structure, can be industrially produced through solid-phase chemical synthesis, can also be industrially applied to preparation of treatment medicines for promoting skin wound repair, and can be used as a candidate polypeptide medicine or a medical beauty product raw material for treating body surface wounds, repairing tissues, burns and skin ulcers, reducing scars and accelerating scar repair.

The invention discloses application of MBD3 as an intervention target in preparation of a neuroblastoma treatment medicine, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, a substance for reducing the expression level of the MBD3 gene or reducing the protein level of the MBD3 is applied to the development of a medicine for treating the neuroblastoma, and it is proved that interference on the expression of the MBD3 gene can induce the G0 / G1 phase cell cycle arrest of neuroblastoma cells and promote cell apoptosis, so that the in-vivo and in-vitro proliferation activity of the neuroblastoma cells is effectively inhibited; the small-molecule drug enbopiravidone can down-regulate the MBD3 protein level and significantly inhibit the growth of neuroblastoma cells. According to the invention, MBD3 is taken as a new target spot for treating neuroblastoma, a new direction is provided for overcoming the limitation of the existing therapy, a scientific basis is provided for developing a novel neuroblastoma treatment strategy based on MBD3 inhibition, and the application has important significance for improving the living quality and survival prognosis of high-risk children.

The invention discloses silkworm pupa protein anti-tumor active peptide as well as a separation and screening method and application thereof. Silkworm chrysalis is dried, smashed and degreased to obtain degreased silkworm chrysalis powder; the preparation method comprises the following steps: dissolving degreased silkworm chrysalis meal into a NaOH solution, stirring, extracting, centrifuging, collecting supernate, adjusting the pH value, centrifuging, collecting protein precipitate, washing the protein precipitate, and freeze-drying to obtain protein powder; adding deionized water into the protein powder, performing ultrasonic oscillation to recover room temperature, adding papain, adjusting pH, stirring for enzymolysis, boiling for quenching, cooling, centrifuging at 4 DEG C, collecting supernatant, freeze-drying to obtain polypeptide powder, separating, collecting and detecting the anti-tumor cell proliferation activity of zymolyte; under the same condition, the zymolyte with the highest antitumor activity is further purified by adopting Sephadex-G15 gel chromatography, the antitumor cell proliferation activity of each component is collected and detected, the active peptide with the best antitumor effect is obtained by screening according to the inhibition ratio, and the active peptide is identified as YASPVH according to the amino acid sequence.